On March 26, 2025, affiliates of Joseph Stilwell, a director of the Company, sold 1,000,000 shares of Common Stock of the Company, as reported by Mr. Stilwell in a Form 4 filed with the Securities and Exchange Commission on March 27, 2025. These sales were made to DCP Fund, DCP Special, and other purchasers. DCP Fund acquired 125,000 shares of Common Stock and DCP Special acquired 460,000 shares of Common Stock, in each case at a price per share of $8.00. On March 31, 2025, certain purchasers, including DCP Fund and DCP Special, entered into option agreements with Stilwell Value LLC, an affiliate of Mr. Stilwell, to acquire an aggregate of 1,750,000 additional shares of Common Stock, at an exercise price of $8.25 per share, which options are exercisable by each investor (and DCP Fund and DCP Special together) in whole, and not in part, on December 29, 2025 and that expire at 5:00 p.m. Eastern Time on December 29, 2025. Pursuant to the option agreement entered into by DCP Fund and DCP Special, DCP Fund acquired the right to purchase 275,000 shares of Common Stock and DCP Special acquired the right to purchase 540,000 shares of Common Stock. A copy of the option agreement entered into by DCP Fund and DCP Special is attached hereto as Exhibit 99.1. On March 31, 2025, DCP Special entered into an option agreement with Oakmont Capital Inc. to acquire 500,000 additional shares of Common Stock, at an exercise price of $8.25 per share, which option is exercisable by DCP Special in whole, and not in part, on December 29, 2025 and that expires at 5:00 p.m. Eastern Time on December 29, 2025. Terence M. Kavanagh, a director of the Company, is the President and a director of Oakmont Capital Inc. and Gregory P. Hannon, a director of the Company, is a vice president and director of Oakmont Capital Inc. A copy of the option agreement entered into by DCP Special is attached hereto as Exhibit 99.2. In addition, DCP Special purchased 3,000 shares of Common Stock on March 27, 2025 for an average price of $7.96 and 21,000 shares of Common Stock on March 28, 2025 for an average price of $7.94. On March 31, 2025, Mr. Patinkin was appointed to the Company's board of directors. Representatives of other acquirers of Common Stock and option agreements were also appointed to the Company's board on the same date. The Reporting Persons acquired the Common Stock reported in this Statement for investment purposes. The Reporting Persons and their affiliates may in the future acquire additional shares of Common Stock or dispose of some or all of the shares of Common Stock held by the Reporting Persons in open-market transactions or privately negotiated transactions, on such terms and at such times as the Reporting Persons may deem advisable. The Reporting Persons may engage in short selling or hedging or similar transactions with respect to the Common Stock, on such terms and at such times as the Reporting Persons may deem advisable, subject to applicable law. The Reporting Persons do not have any present plan or proposal that would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein, or as may be proposed by Mr. Patinkin in his capacity as a director of the Company or by the Company's board of directors with his participation. The Reporting Persons intend to review their investment in the Company on a continuing basis. Depending on various factors including, without limitation, the Company's financial position, the price levels of the securities of the Company, conditions in the securities markets, and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Company as they deem appropriate, including, without limitation, engaging in communications with management and/or the board of directors of the Company and their advisors, engaging in discussions with stockholders of the Company and others about the Company and the Reporting Persons' investment, making proposals to the Company concerning changes to the capitalization, the ownership structure, the structure, composition, and skill sets of the board of directors and senior management or the operations of the Company, purchasing additional securities of the Company, selling some or all of such securities, entering into financial instruments or other agreements that increase or decrease the Reporting Persons' economic or beneficial exposure with respect to their investment in the Company, engaging in short selling of or any hedging or similar transaction with respect to the securities of the Company, including swaps and other derivative instruments, or changing their intention with respect to any and all matters referred to in Item 4.